Evaluating Tau PET/CT for Diagnosing Tau-Related Diseases
Tau PET/CT in Various Tau-Related Disease Patients
This study is testing a new type of imaging scan to see if it can help doctors better diagnose Tau-related diseases in adults with suspected or diagnosed tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 2 sites (Hefei, Anhui and 1 other locations) |
| Trial ID | NCT06690983 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with various Tau-related diseases. Participants, who are adults with suspected or diagnosed malignant tumors, undergo PET/CT scans to assess lesion uptake and quantify results using maximum standard uptake value (SUVmax). The study aims to calculate key diagnostic metrics such as sensitivity, specificity, and accuracy of the imaging technique.
Who should consider this trial
Good fit: Ideal candidates include adult patients with suspected or newly diagnosed malignant tumors related to Tauopathies.
Not a fit: Patients with non-malignant lesions or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnostic accuracy for patients with Tau-related diseases, leading to better treatment decisions.
How similar studies have performed: While this approach is novel in the context of Tau-related diseases, similar imaging techniques have shown promise in other neurodegenerative conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: \- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where this trial is running
Hefei, Anhui and 1 other locations
- The First Affiliated Hospital of University of Science and Technology of China — Hefei, Anhui, China (Recruiting)
- Tianjin Medical University General Hospital — Tianjin, Tianjin Municipality, China (Recruiting)
Study contacts
- Study coordinator: Ying Wang, MD
- Email: macrossplusvoices@163.com
- Phone: +8618702292537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.